ASXL1 gene mutations, observed in 15–20% of MDS patients, are associated with an inferior prognosis in MDS cases, resulting in a shorter OS and an increased risk of progression to AML [17]. The gene discussed is ASXL1; the disease is acute myeloid leukemia.